dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade Federal de São Paulo (UNIFESP)
dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniv Oxford
dc.date.accessioned2014-05-20T14:00:27Z
dc.date.available2014-05-20T14:00:27Z
dc.date.created2014-05-20T14:00:27Z
dc.date.issued2007-06-15
dc.identifierInternational Journal of Cancer. Malden: Wiley-blackwell, v. 120, n. 12, p. 2582-2589, 2007.
dc.identifier0020-7136
dc.identifierhttp://hdl.handle.net/11449/21381
dc.identifier10.1002/ijc.22639
dc.identifierWOS:000245873000007
dc.description.abstractAnnexin 1 protein (ANXA1) expression was evaluated in tumor and mast cells in human larynx cancer and control epithelium. The effect of the exogenous ANXA1 (peptide Ac 2-26) was also examined during the cellular growth of the Hep-2 human larynx epidermoid carcinoma cell line. This peptide inhibited the proliferation of the Hep-2 cells within 144 hr. In surgical tissue specimens from 20 patients with larynx cancer, ultrastructural immunocytochemistry analysis showed in vivo down-regulation of ANXA1 expression in the tumor and increased in mast cells and Hep-2 cells treated with peptide Ac2-26. Combined in vivo and in vitro analysis demonstrated that ANXA1 plays a regulatory role in laryngeal cancer cell growth. We believe that a better understanding of the regulatory mechanisms of ANXA1 in tumor and mast cells may lead to future biological targets for the therapeutic intervention of human larynx cancer. (c) 2007 Wiley-Liss, Inc.
dc.languageeng
dc.publisherWiley-Blackwell
dc.relationInternational Journal of Cancer
dc.relation7.360
dc.relation3,152
dc.rightsAcesso aberto
dc.sourceWeb of Science
dc.subjecthuman mast cells
dc.subjectHep-2 cells
dc.subjectannexin 1
dc.subjectlarynx tumor
dc.subjectultrastructural immunocytochemistry
dc.titleAnnexin 1: differential expression in tumor and mast cells in human larynx cancer
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución